Multispectral Optoacoustic Tomography in Head and Neck Squamous Cell Cancer
NCT ID: NCT06477003
Last Updated: 2025-09-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
100 participants
INTERVENTIONAL
2025-09-30
2027-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Non-invasive Preoperative Tissue Evaluation in Head and Neck Tumor Patients Using Multispectral Optoacoustic Tomography (MSOT)
NCT06716892
Multiparametric Photoacoustic Imaging in the Course of Radiation Therapy of Malignant Head and Neck Tumors
NCT04437030
Stereotactic Radiosurgery in Patients With Head and Neck Region Tumours
NCT06472570
The eValuation of Sources of vIBRAtioN for Vibrational Shear Wave elasTography
NCT07098819
Photoacoustic Imaging of Head and Neck Tumours
NCT05073809
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm 1 - surgery patients
70 patients with clinically confirmed metastatic head and neck squamous cell carcinomas (N+ HNSCC) planned for definitive surgery will be imaged using the MSOT device prior to surgery. Skin temperature will be measured prior to and after MSOT imaging to assess for safety.
Multispectral Optoacoustic Tomography
The MSOT device will be used to take images of the tumor or affected lymph nodes of patients with head and neck squamous cell carcinoma.
Temperature Measurement
The temperature of the skin will be measured prior to and after MSOT imaging.
Arm 2 - radiotherapy patients
30 patients with clinically confirmed metastatic head and neck squamous cell carcinomas (N+ HNSCC) planned for definitive radiotherapy (RT) (+/- chemo) will be imaged using the MSOT device before, during, and after radiotherapy. 15 patients will be treated with photon RT and 15 patients will be treated with proton therapy. Skin temperature will be measured prior to and after MSOT imaging to assess for safety.
Multispectral Optoacoustic Tomography
The MSOT device will be used to take images of the tumor or affected lymph nodes of patients with head and neck squamous cell carcinoma.
Temperature Measurement
The temperature of the skin will be measured prior to and after MSOT imaging.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Multispectral Optoacoustic Tomography
The MSOT device will be used to take images of the tumor or affected lymph nodes of patients with head and neck squamous cell carcinoma.
Temperature Measurement
The temperature of the skin will be measured prior to and after MSOT imaging.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Written informed consent signed and dated by the patient prior to the performance of the MSOT
* At least 18 years-of-age at the time of signature of the informed consent form (ICF)
* Patients planned for curative intent therapy
* Patient available for the study duration
* Patients of childbearing potential must have a negative pregnancy test prior to the study entry.
* Patients of childbearing potential must use an effective form of contraceptive as per the protocol.
Exclusion Criteria
* Intent of treatment palliative
* Women who are pregnant
* Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety of efficacy assessment of the investigational regimen should be included.
* Psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol and/or follow-up procedures outlined in the protocol.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Oklahoma
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Christina Henson, MD
Role: PRINCIPAL_INVESTIGATOR
University of Oklahoma
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
OU-SCC-MOTORX
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.